Download PDF
Z Gastroenterol 2023; 61(06): 690-700
DOI: 10.1055/a-1890-6015
Übersicht

Questions to consider when caring for patients with ulcerative colitis

Alltagsrelevante Fragen für die Versorgung von Patient*innen mit Colitis ulcerosa
Peter Hasselblatt
1   Department of Medicine II, University Hospital Freiburg, Freiburg, Germany
,
Wolfgang Reindl
2   Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
,
Annika Gauss
3   University Hospital Heidelberg, Heidelberg, Germany (Ringgold ID: RIN27178)
,
Hannes Neeff
4   Dept. of General and Visceral Surgery, Medical Center – University of Freiburg, Freiburg, Germany
,
Stefano Fusco
5   Department of Gastroenterology, Eberhard-Karls-Universität Tübingen Medizinische Fakultät, Tübingen, Germany (Ringgold ID: RIN54188)
,
Jochen Klaus
6   Innere I, Uniklinik Ulm, Ulm, Germany
› Author AffiliationsThis work was supported by funds from the state of Baden-Wuerttemberg within the Centers for Personalized Medicine Baden-Wuerttemberg (ZPM).
› Further Information
Also available at
    Permissions and Reprints

Abstract

Although the management of patients with ulcerative colitis (UC) is well defined by national and international guidelines, there are many debates and open questions related to daily care of UC patients. Here, we aimed to review topics with high clinical relevance including therapy algorithms, potential biomarkers for disease prognosis and response to therapy, the role of interventions targeting the gut microbiota, insights from head-to-head trials, novel UC medications, exit strategies, the impact of COVID19 on UC, care of patients with acute severe disease, cancer screening, and the role of surgery.

Zusammenfassung

Die aktuellen Therapiestandards für Patientinnen und Patienten mit Colitis ulcerosa werden durch nationale und internationale Leitlinien gut definiert. Dennoch gibt es im klinischen Alltag viele Punkte, die kontrovers diskutiert werden oder bei denen Unsicherheiten bestehen. In dieser Übersichtsarbeit wird eine Auswahl an Themen mit hoher klinischer Relevanz diskutiert. Diese umfassen aktuelle Therapiealgorithmen, potenzielle Biomarker für Krankheitsprognose und Therapieansprechen, Perspektiven für den therapeutischen Einsatz eines fäkalen Mikrobiotatransfers, die Bedeutung aktueller Head-to-Head-Studien, neue Medikamente, EXIT-Strategien für verschiedene Medikamente, den Einfluss der Colitis ulcerosa bzw. damit verbundener Therapien auf eine COVID-19-Erkrankung bzw. Impfung, das Management der schweren akuten Colitis, die Darmkrebsvorsorge sowie die Indikationsstellung und das Vorgehen bei Proktokolektomie und Pouchanlage.

Schlüsselwörter

Darm - chronisch entzündliche Darmerkrankung - Colitis ulcerosa - Personalisierte Medizin - Fäkaler Mikrobiotatransfer - Biologika - Darmkrebsvorsorge - Proktokolektomie

Keywords

Intestine - inflammatory bowel disease - ulcerative colitis - personalized medicine - fecal microbiota transfer - biologicals - colorectal cancer screening - proctocolectomy


Publication History

Received: 26 February 2022

Accepted after revision: 13 June 2022

Article published online:
18 October 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Raine T, Bonovas S, Burisch J. et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis 2021;
    CrossrefPubMedSearch in Google Scholar
  • 2 Kucharzik T, Dignass AU, Atreya R. et al. Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Z Gastroenterol 2020; 58: e241-e326
    Thieme ConnectPubMedSearch in Google Scholar
  • 3 Turner D, Ricciuto A, Lewis A. et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021; 160: 1570-1583
    CrossrefPubMedSearch in Google Scholar
  • 4 Ungaro R, Colombel JF, Lissoos T. et al. A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. Am J Gastroenterol 2019; 114: 874-883
    CrossrefPubMedSearch in Google Scholar
  • 5 Arias MT, Vande Casteele N, Vermeire S. et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13: 531-538
    CrossrefPubMedSearch in Google Scholar
  • 6 Restellini S, Chao CY, Martel M. et al. Clinical Parameters Correlate With Endoscopic Activity of Ulcerative Colitis: A Systematic Review. Clin Gastroenterol Hepatol 2019; 17: 1265-1275 e1268
    CrossrefPubMedSearch in Google Scholar
  • 7 Stevens TW, Gecse K, Turner JR. et al. Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2021; 19: 2333-2342
    CrossrefPubMedSearch in Google Scholar
  • 8 Maaser C, Petersen F, Helwig U. et al. Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study. Gut 2020; 69: 1629-1636
    CrossrefPubMedSearch in Google Scholar
  • 9 Monstad IL, Solberg IC, Cvancarova M. et al. Outcome of Ulcerative Colitis 20 Years after Diagnosis in a Prospective Population-based Inception Cohort from South-Eastern Norway, the IBSEN Study. J Crohns Colitis 2021; 15: 969-979
    CrossrefPubMedSearch in Google Scholar
  • 10 Magro F, Alves C, Lopes J. et al. Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy. Clin Gastroenterol Hepatol 2021; 19: 2567-2576 e2569
    CrossrefPubMedSearch in Google Scholar
  • 11 Colman RJ, Rubin DT. Histological inflammation increases the risk of colorectal neoplasia in ulcerative colitis: a systematic review. Intest Res 2016; 14: 202-210
    CrossrefPubMedSearch in Google Scholar
  • 12 Le Berre C, Ricciuto A, Peyrin-Biroulet L. et al. Evolving short- and long-term goals of management of IBD: getting it right, making it last. Gastroenterology 2021;
    CrossrefPubMedSearch in Google Scholar
  • 13 Verstockt B, Noor NM, Marigorta UM. et al. Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy. J Crohns Colitis 2021; 15: 1431-1442
    CrossrefPubMedSearch in Google Scholar
  • 14 Verstockt B, Parkes M, Lee J. How do we predict a patient’s disease course and whether they will respond to specific treatments?. Gastroenterology 2021;
    CrossrefPubMedSearch in Google Scholar
  • 15 Magro F, Dias CC, Portela F. et al. Development and Validation of Risk Matrices Concerning Ulcerative Colitis Outcomes-Bayesian Network Analysis. J Crohns Colitis 2019; 13: 401-409
    CrossrefPubMedSearch in Google Scholar
  • 16 Lee JC, Lyons PA, McKinney EF. et al. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest 2011; 121: 4170-4179
    CrossrefPubMedSearch in Google Scholar
  • 17 McKinney EF, Lee JC, Jayne DR. et al. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 2015; 523: 612-616
    CrossrefPubMedSearch in Google Scholar
  • 18 Biasci D, Lee JC, Noor NM. et al. A blood-based prognostic biomarker in IBD. Gut 2019; 68: 1386-1395
    CrossrefPubMedSearch in Google Scholar
  • 19 Parkes M, Noor NM, Dowling F. et al. PRedicting Outcomes For Crohn’s dIsease using a moLecular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial. BMJ Open 2018; 8: e026767
    CrossrefPubMedSearch in Google Scholar
  • 20 Aden K, Rehman A, Waschina S. et al. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases. Gastroenterology 2019; 157: 1279-1292 e1211
    CrossrefPubMedSearch in Google Scholar
  • 21 Feagan BG, Danese S, Loftus EV. et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet 2021; 397: 2372-2384
    CrossrefPubMedSearch in Google Scholar
  • 22 Sandborn WJ, Feagan BG, D’Haens G. et al. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2021; 385: 1280-1291
    CrossrefPubMedSearch in Google Scholar
  • 23 Sandborn WJ, Su C, Sands BE. et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2017; 376: 1723-1736
    CrossrefPubMedSearch in Google Scholar
  • 24 Sands BE, Sandborn WJ, Panaccione R. et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2019; 381: 1201-1214
    CrossrefPubMedSearch in Google Scholar
  • 25 Sazonovs A, Kennedy NA, Moutsianas L. et al. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease. Gastroenterology 2020; 158: 189-199
    CrossrefPubMedSearch in Google Scholar
  • 26 Atreya R, Neumann H, Neufert C. et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn’s disease. Nat Med 2014; 20: 313-318
    CrossrefPubMedSearch in Google Scholar
  • 27 West NR, Hegazy AN, Owens BMJ. et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med 2017; 23: 579-589
    CrossrefPubMedSearch in Google Scholar
  • 28 Verstockt B, Verstockt S, Dehairs J. et al. Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease. EBioMedicine 2019; 40: 733-742
    CrossrefPubMedSearch in Google Scholar
  • 29 Saurer L, Rihs S, Birrer M. et al. Elevated levels of serum-soluble triggering receptor expressed on myeloid cells-1 in patients with IBD do not correlate with intestinal TREM-1 mRNA expression and endoscopic disease activity. J Crohns Colitis 2012; 6: 913-923
    CrossrefPubMedSearch in Google Scholar
  • 30 Friedrich M, Pohin M, Jackson MA. et al. IL-1-driven stromal-neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies. Nat Med 2021; 27: 1970-1981
    CrossrefPubMedSearch in Google Scholar
  • 31 Jessen B, Rodriguez-Sillke Y, Sonnenberg E. et al. Level of Tumor Necrosis Factor Production by Stimulated Blood Mononuclear Cells Can Be Used to Predict Response of Patients With Inflammatory Bowel Diseases to Infliximab. Clin Gastroenterol Hepatol 2021; 19: 721-731 e721
    CrossrefPubMedSearch in Google Scholar
  • 32 Verstockt B, Verstockt S, Veny M. et al. Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020; 18: 1142-1151 e1110
    CrossrefPubMedSearch in Google Scholar
  • 33 Gottlieb ZS, Sands BE. Personalized Medicine with IL-23 Blockers: Myth or Reality?. J Crohns Colitis 2021;
    CrossrefPubMedSearch in Google Scholar
  • 34 Sandborn WJ, Armuzzi A, Liguori G. et al. Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis. Inflamm Bowel Dis 2021;
    CrossrefPubMedSearch in Google Scholar
  • 35 Kruis W, Fric P, Pokrotnieks J. et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623
    CrossrefPubMedSearch in Google Scholar
  • 36 van Nood E, Vrieze A, Nieuwdorp M. et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-415
    CrossrefPubMedSearch in Google Scholar
  • 37 Machiels K, Joossens M, Sabino J. et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014; 63: 1275-1283
    CrossrefPubMedSearch in Google Scholar
  • 38 McIlroy J, Ianiro G, Mukhopadhya I. et al. Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management. Aliment Pharmacol Ther 2018; 47: 26-42
    CrossrefPubMedSearch in Google Scholar
  • 39 Moayyedi P, Surette MG, Kim PT. et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology 2015; 149: 102-109 e106
    CrossrefPubMedSearch in Google Scholar
  • 40 Rossen NG, Fuentes S, van der Spek MJ. et al. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology 2015; 149: 110-118 e114
    CrossrefPubMedSearch in Google Scholar
  • 41 Paramsothy S, Kamm MA, Kaakoush NO. et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 2017; 389: 1218-1228
    CrossrefPubMedSearch in Google Scholar
  • 42 Costello SP, Hughes PA, Waters O. et al. Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial. JAMA 2019; 321: 156-164
    CrossrefPubMedSearch in Google Scholar
  • 43 Vermeire S, Joossens M, Verbeke K. et al. Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. J Crohns Colitis 2016; 10: 387-394
    CrossrefPubMedSearch in Google Scholar
  • 44 Lima SF, Gogokhia L, Viladomiu M. et al. Transferable Immunoglobulin A-Coated Odoribacter splanchnicus in Responders to Fecal Microbiota Transplantation for Ulcerative Colitis Limits Colonic Inflammation. Gastroenterology 2022; 162: 166-178
    CrossrefPubMedSearch in Google Scholar
  • 45 Brezina J, Bajer L, Wohl P. et al. Fecal Microbial Transplantation versus Mesalamine Enema for Treatment of Active Left-Sided Ulcerative Colitis-Results of a Randomized Controlled Trial. J Clin Med 2021; 10
    CrossrefPubMedSearch in Google Scholar
  • 46 Haifer C, Paramsothy S, Kaakoush NO. et al. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 2022; 7: 141-151
    CrossrefPubMedSearch in Google Scholar
  • 47 Crothers JW, Chu ND, Nguyen LTT. et al. Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study. BMC Gastroenterol 2021; 21: 281
    CrossrefPubMedSearch in Google Scholar
  • 48 Ott SJ, Waetzig GH, Rehman A. et al. Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection. Gastroenterology 2017; 152: 799-811 e797
    CrossrefPubMedSearch in Google Scholar
  • 49 Stallmach A, Grunert P, Stallhofer J. et al. Transfer of FRozen Encapsulated multi-donor Stool filtrate for active ulcerative Colitis (FRESCO): study protocol for a prospective, multicenter, double-blind, randomized, controlled trial. Trials 2022; 23: 173
    CrossrefPubMedSearch in Google Scholar
  • 50 Lasa JS, Olivera PA, Danese S. et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2022; 7: 161-170
    CrossrefPubMedSearch in Google Scholar
  • 51 Burr NE, Gracie DJ, Black CJ. et al. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut 2021;
    CrossrefPubMedSearch in Google Scholar
  • 52 Peyrin-Biroulet L, Lopez A, Sandborn W. Head-to-head Comparative Studies: Challenges and Opportunities?. J Crohns Colitis 2017; 11: S567-S575
    CrossrefPubMedSearch in Google Scholar
  • 53 Laharie D, Bourreille A, Branche J. et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-1915
    CrossrefPubMedSearch in Google Scholar
  • 54 Williams JG, Alam MF, Alrubaiy L. et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol 2016; 1: 15-24
    CrossrefPubMedSearch in Google Scholar
  • 55 Sands BE, Peyrin-Biroulet L, Loftus EV. et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med 2019; 381: 1215-1226
    CrossrefPubMedSearch in Google Scholar
  • 56 Rubin DT, Dotan I, DuVall A. et al. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol 2022; 7: 17-27
    CrossrefPubMedSearch in Google Scholar
  • 57 Danese S, Colombel JF, Lukas M. et al. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol Hepatol 2022; 7: 118-127
    CrossrefPubMedSearch in Google Scholar
  • 58 Pouillon L, Travis S, Bossuyt P. et al. Head-to-head trials in inflammatory bowel disease: past, present and future. Nat Rev Gastroenterol Hepatol 2020; 17: 365-376
    CrossrefPubMedSearch in Google Scholar
  • 59 Peyrin-Biroulet L, Hart A, Bossuyt P. et al. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol 2022; 7: 128-140
    CrossrefPubMedSearch in Google Scholar
  • 60 Vermeire S, Lakatos PL, Ritter T. et al. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Lancet Gastroenterol Hepatol 2022; 7: 28-37
    CrossrefPubMedSearch in Google Scholar
  • 61 Almradi A, Hanzel J, Sedano R. et al. Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease. BioDrugs 2020; 34: 713-721
    CrossrefPubMedSearch in Google Scholar
  • 62 Sandborn WJ, Ferrante M, Bhandari BR. et al. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2022; 20: 105-115 e114
    CrossrefPubMedSearch in Google Scholar
  • 63 d’Haens G, Kobayashi T, Morris N. et al. Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 LUCENT-1 study. J Crohns Colitis 2022: i028
    PubMed
  • 64 D’Amico F, Allocca M, Fiorino G. Positioning ozanimod in ulcerative colitis: restoring leukocyte traffic under control. Gastroenterology 2021;
    CrossrefPubMedSearch in Google Scholar
  • 65 Sandborn WJ, Peyrin-Biroulet L, Zhang J. et al. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology 2020; 158: 550-561
    CrossrefPubMedSearch in Google Scholar
  • 66 Winthrop KL, Tanaka Y, Takeuchi T. et al. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Ann Rheum Dis 2022; 81: 184-192
    CrossrefPubMedSearch in Google Scholar
  • 67 Sandborn WJ, Ghosh S, Panes J. et al. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. Gastroenterology 2020; 158: 2139-2149 e2114
    CrossrefPubMedSearch in Google Scholar
  • 68 Atreya R, Peyrin-Biroulet L, Klymenko A. et al. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. Lancet Gastroenterol Hepatol 2020; 5: 1063-1075
    CrossrefPubMedSearch in Google Scholar
  • 69 Doherty G, Katsanos KH, Burisch J. et al. European Crohn’s and Colitis Organisation Topical Review on Treatment Withdrawal [‘Exit Strategies’] in Inflammatory Bowel Disease. J Crohns Colitis 2018; 12: 17-31
    CrossrefPubMedSearch in Google Scholar
  • 70 Ardizzone S, Petrillo M, Imbesi V. et al. Is maintenance therapy always necessary for patients with ulcerative colitis in remission?. Aliment Pharmacol Ther 1999; 13: 373-379
    CrossrefPubMedSearch in Google Scholar
  • 71 Hawthorne AB, Logan RF, Hawkey CJ. et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 20-22
    CrossrefPubMedSearch in Google Scholar
  • 72 Calafat M, Manosa M, Canete F. et al. Increased risk of thiopurine-related adverse events in elderly patients with IBD. Aliment Pharmacol Ther 2019; 50: 780-788
    CrossrefPubMedSearch in Google Scholar
  • 73 Beaugerie L, Brousse N, Bouvier AM. et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-1625
    CrossrefPubMedSearch in Google Scholar
  • 74 Kobayashi T, Motoya S, Nakamura S. et al. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol 2021; 6: 429-437
    CrossrefPubMedSearch in Google Scholar
  • 75 Ungaro RC, Limketkai BN, Jensen CB. et al. Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. Gut 2019; 68: 977-984
    CrossrefPubMedSearch in Google Scholar
  • 76 Bernstein CN, Tenakoon A, Singh H. et al. Continued 5ASA use after initiation of anti-TNF or immunomodulator confers no benefit in IBD: a population-based study. Aliment Pharmacol Ther 2021; 54: 814-832
    CrossrefPubMedSearch in Google Scholar
  • 77 Singh S, Kim J, Zhu W. et al. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Aliment Pharmacol Ther 2020; 52: 481-491
    CrossrefPubMedSearch in Google Scholar
  • 78 Panaccione R, Ghosh S, Middleton S. et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146: 392-400 e393
    CrossrefPubMedSearch in Google Scholar
  • 79 Filippi J, Laharie D, Michiels C. et al. Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experience. J Crohns Colitis 2015; 9: 252-258
    CrossrefPubMedSearch in Google Scholar
  • 80 Martin A, Nachury M, Peyrin-Biroulet L. et al. Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. J Crohns Colitis 2020; 14: 896-903
    CrossrefPubMedSearch in Google Scholar
  • 81 Brenner EJ, Ungaro RC, Gearry RB. et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology 2020; 159: 481-491 e483
    CrossrefPubMedSearch in Google Scholar
  • 82 Ungaro RC, Brenner EJ, Gearry RB. et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 2021; 70: 725-732
    CrossrefPubMedSearch in Google Scholar
  • 83 Agrawal M, Brenner EJ, Zhang X. et al. Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry. Inflamm Bowel Dis 2021; 27: 585-589
    CrossrefPubMedSearch in Google Scholar
  • 84 Khan N, Mahmud N, Trivedi C. et al. Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System. Gut 2021; 70: 1657-1664
    CrossrefPubMedSearch in Google Scholar
  • 85 Magro F, Rahier JF, Abreu C. et al. Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do’s and Don’ts from the ECCO-COVID Taskforce. J Crohns Colitis 2020; 14: S798-S806
    CrossrefPubMedSearch in Google Scholar
  • 86 Stallmach A, Sturm A, Blumenstein I. et al. Addendum to S3-Guidelines Crohn’s disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic – open questions and answers. Z Gastroenterol 2020; 58: 982-1002
    Thieme ConnectPubMedSearch in Google Scholar
  • 87 Siegel CA, Melmed GY, McGovern DP. et al. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut 2021; 70: 635-640
    CrossrefPubMedSearch in Google Scholar
  • 88 Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A. et al. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFalpha. Gastroenterology 2022; 162: 454-467
    CrossrefPubMedSearch in Google Scholar
  • 89 Khan N, Mahmud N. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications. Gastroenterology 2021; 161: 827-836
    CrossrefPubMedSearch in Google Scholar
  • 90 Lin S, Kennedy NA, Saifuddin A. et al. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nat Commun 2022; 13: 1379
    CrossrefPubMedSearch in Google Scholar
  • 91 Hindryckx P, Jairath V, D’Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol 2016; 13: 654-664
    CrossrefPubMedSearch in Google Scholar
  • 92 Kappelman MD, Rifas-Shiman SL, Porter CQ. et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology 2008; 135: 1907-1913
    CrossrefPubMedSearch in Google Scholar
  • 93 Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2: 1041-1048
    CrossrefPubMedSearch in Google Scholar
  • 94 Gisbert JP, Chaparro M. Acute severe ulcerative colitis: State of the art treatment. Best Pract Res Clin Gastroenterol 2018; 32: 59-69
    CrossrefPubMedSearch in Google Scholar
  • 95 Moore AC, Bressler B. Acute Severe Ulcerative Colitis: The Oxford Criteria No Longer Predict In-Hospital Colectomy Rates. Dig Dis Sci 2020; 65: 576-580
    CrossrefPubMedSearch in Google Scholar
  • 96 Lennard-Jones JE, Ritchie JK, Hilder W. et al. Assessment of severity in colitis: a preliminary study. Gut 1975; 16: 579-584
    CrossrefPubMedSearch in Google Scholar
  • 97 Grant RK, Jones GR, Plevris N. et al. The ACE (Albumin, CRP and Endoscopy) Index in Acute Colitis: A Simple Clinical Index on Admission that Predicts Outcome in Patients With Acute Ulcerative Colitis. Inflamm Bowel Dis 2021; 27: 451-457
    CrossrefPubMedSearch in Google Scholar
  • 98 Ma R, Meng R, Zhang X. et al. Correlation between fecal calprotectin, ulcerative colitis endoscopic index of severity and clinical outcome in patients with acute severe colitis. Exp Ther Med 2020; 20: 1498-1504
    CrossrefPubMedSearch in Google Scholar
  • 99 Lichtiger S, Present DH, Kornbluth A. et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-1845
    Search in Google Scholar
  • 100 Van Assche G, D’Haens G, Noman M. et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-1031
    CrossrefPubMedSearch in Google Scholar
  • 101 Spinelli A, Bonovas S, Burisch J. et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. J Crohns Colitis 2021;
    CrossrefPubMedSearch in Google Scholar
  • 102 Feuerstein JD, Isaacs KL, Schneider Y. et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology 2020; 158: 1450-1461
    CrossrefPubMedSearch in Google Scholar
  • 103 Gibson DJ, Heetun ZS, Redmond CE. et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13: 330-335 e331
    CrossrefPubMedSearch in Google Scholar
  • 104 Berinstein JA, Sheehan JL, Dias M. et al. Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study. Clin Gastroenterol Hepatol 2021; 19: 2112-2120 e2111
    CrossrefPubMedSearch in Google Scholar
  • 105 Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535
    CrossrefPubMedSearch in Google Scholar
  • 106 Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol 2008; 14: 3937-3947
    CrossrefPubMedSearch in Google Scholar
  • 107 Zheng HH, Jiang XL. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies. Eur J Gastroenterol Hepatol 2016; 28: 383-390
    CrossrefPubMedSearch in Google Scholar
  • 108 Wijnands AM, de Jong ME, Lutgens M. et al. Prognostic Factors for Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: Systematic Review and Meta-analysis. Gastroenterology 2021; 160: 1584-1598
    CrossrefPubMedSearch in Google Scholar
  • 109 Olen O, Erichsen R, Sachs MC. et al. Colorectal cancer in Crohn’s disease: a Scandinavian population-based cohort study. Lancet Gastroenterol Hepatol 2020; 5: 475-484
    CrossrefPubMedSearch in Google Scholar
  • 110 Cassinotti A, Fociani P, Duca P. et al. Modified Kudo classification can improve accuracy of virtual chromoendoscopy with FICE in endoscopic surveillance of ulcerative colitis. Endosc Int Open 2020; 8: E1414-E1422
    Thieme ConnectPubMedSearch in Google Scholar
  • 111 Klepp P, Tollisen A, Roseth A. et al. Real-life chromoendoscopy for dysplasia surveillance in ulcerative colitis. World J Gastroenterol 2018; 24: 4069-4076
    CrossrefPubMedSearch in Google Scholar
  • 112 Bisschops R, Bessissow T, Joseph JA. et al. Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial. Gut 2018; 67: 1087-1094
    CrossrefPubMedSearch in Google Scholar
  • 113 Har-Noy O, Katz L, Avni T. et al. Chromoendoscopy, Narrow-Band Imaging or White Light Endoscopy for Neoplasia Detection in Inflammatory Bowel Diseases. Dig Dis Sci 2017; 62: 2982-2990
    CrossrefPubMedSearch in Google Scholar
  • 114 Resende RH, Ribeiro IB, de Moura DTH. et al. Surveillance in inflammatory bowel disease: is chromoendoscopy the only way to go? A systematic review and meta-analysis of randomized clinical trials. Endosc Int Open 2020; 8: E578-E590
    Thieme ConnectPubMedSearch in Google Scholar
  • 115 Magro F, Gionchetti P, Eliakim R. et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis 2017; 11: 649-670
    CrossrefPubMedSearch in Google Scholar
  • 116 Bernstein CN, Ng SC, Lakatos PL. et al. A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis 2013; 19: 2001-2010
    CrossrefPubMedSearch in Google Scholar
  • 117 Zhao M, Sall Jensen M, Knudsen T. et al. Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases – a Danish nationwide cohort study. Aliment Pharmacol Ther 2022; 55: 541-557
    CrossrefPubMedSearch in Google Scholar
  • 118 Heikens JT, de Vries J, van Laarhoven CJ. Quality of life, health-related quality of life and health status in patients having restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis: a systematic review. Colorectal Dis 2012; 14: 536-544
    CrossrefPubMedSearch in Google Scholar
  • 119 Gu J, Stocchi L, Remzi F. et al. Factors associated with postoperative morbidity, reoperation and readmission rates after laparoscopic total abdominal colectomy for ulcerative colitis. Colorectal Dis 2013; 15: 1123-1129
    CrossrefPubMedSearch in Google Scholar
  • 120 Boldovjakova D, Scrimgeour DSG, Parnaby CN. et al. Improved outcomes for patients undergoing colectomy for acute severe inflammatory colitis by adopting a multi-disciplinary care bundle. J Gastrointest Surg 2022; 26: 218-220
    CrossrefPubMedSearch in Google Scholar
  • 121 Kaplan GG, McCarthy EP, Ayanian JZ. et al. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology 2008; 134: 680-687
    CrossrefPubMedSearch in Google Scholar
  • 122 Quaresma AB, Barauna F, Teixeira FV. et al. Exploring the Relationship between Biologics and Postoperative Surgical Morbidity in Ulcerative Colitis: A Review. J Clin Med 2021; 10
    CrossrefPubMedSearch in Google Scholar
  • 123 Flynn J, Larach JT, Kong JCH. et al. Robotic versus laparoscopic ileal pouch-anal anastomosis (IPAA): a systematic review and meta-analysis. Int J Colorectal Dis 2021; 36: 1345-1356
    CrossrefPubMedSearch in Google Scholar